Skip to main content
Top
Published in: Journal of Cardiothoracic Surgery 1/2023

Open Access 01-12-2023 | Heart Failure | Research

Short-term study of atrial shunt and improvement of functional mitral regurgitation

Authors: Xiaoke Shang, Mei Liu, Yucheng Zhong, Xueli Wang, Song Chen, Xiaojuan Fu, Ming Sun, Geng Li, Mingxing Xie, Guangyuan Song, Da Zhu, Changdong Zhang, Nianguo Dong

Published in: Journal of Cardiothoracic Surgery | Issue 1/2023

Login to get access

Abstract

Background

This study used an atrial septal shunt to compare the treatment progress and prognosis for patients with heart failure (HF) who have different ejection fractions.

Methods

Twenty HF patients with pulmonary hypertension, who required atrial septal shunt therapy, were included in this study. The patients underwent surgery between December 2012 and December 2020. They were divided into two groups based on their ejection fraction: a group with reduced ejection fraction (HFrEF) and a group with preserved ejection fraction(HFpEF) + mid-range ejection fraction (HfmrEF). Echocardiography was utilized to evaluate parameters such as left ventricular dimension (LVD), left ventricular ejection fraction (LVEF), and left ventricular end-diastolic volume (LVEDV). Hemodynamic parameters were measured using cardiac catheterization. The patient's cardiac function was assessed using the six-minute walking test (6MWT), KCCQ score, NYHA classification, and the degree of functional mitral regurgitation (FMR). Followed-up visits were conducted at 1, 3, and 6 months, and any adverse effects were recorded.

Results

The LVEF values were consistently higher in the HFpEF+HFmrEF group than HFrEF group at all periods (P < 0.05). Differences in LVD were observed between the two groups before the surgery. Statistically, significant differences were found at the preoperative stage, 1 month, and 3 months (P < 0.05, respectively). However, the LVEDV showed a significant difference between the two groups only at 3 months (P = 0.049). Notably, there were notable variations in LAPm, LAPs, and the pressure gradient between the LA-RA gradient at baeline, after implantation, and during the 6 months follow-up (all P < 0.05).

Conclusion

Following treatment, the HFpEF+HFmrEF group exhibited more significant improvements in echocardiographic and cardiac catheterization indices than the HFrEF group. However, there was no statistically significant difference between the two groups regarding the 6MWT and KCCQ scores. It is important to note that the findings of this study still require further investigation in a large sample size of patients.
Literature
1.
2.
3.
go back to reference Galiè N, McLaughlin VV, Rubin LJ, Simonneau G. An overview of the 6th World Symposium on Pulmonary Hypertension. Eur Respir J. 2019, 53(1). Galiè N, McLaughlin VV, Rubin LJ, Simonneau G. An overview of the 6th World Symposium on Pulmonary Hypertension. Eur Respir J. 2019, 53(1).
6.
go back to reference Murphy C, Zafar H, Sharif F. An updated review of cardiac devices in heart failure. Ir J Med Sci. 2017;186(4):909–19.PubMedCrossRef Murphy C, Zafar H, Sharif F. An updated review of cardiac devices in heart failure. Ir J Med Sci. 2017;186(4):909–19.PubMedCrossRef
7.
go back to reference Schleifer JW, Mookadam F, Kransdorf EP, Nanda U, Adams JC, Cha S, Pajaro OE, Steidley DE, Scott RL, Carvajal T. Effect of continued cardiac resynchronization therapy on ventricular arrhythmias after left ventricular assist device implantation. Am J Cardiol. 2016;118(4):556–9.PubMedCrossRef Schleifer JW, Mookadam F, Kransdorf EP, Nanda U, Adams JC, Cha S, Pajaro OE, Steidley DE, Scott RL, Carvajal T. Effect of continued cardiac resynchronization therapy on ventricular arrhythmias after left ventricular assist device implantation. Am J Cardiol. 2016;118(4):556–9.PubMedCrossRef
8.
go back to reference Lin A, Ho G. Cardiac resynchronization therapy in patients with left ventricular assist devices. In: Case-based device therapy for heart failure. Springer; 2021. p. 337–41. Lin A, Ho G. Cardiac resynchronization therapy in patients with left ventricular assist devices. In: Case-based device therapy for heart failure. Springer; 2021. p. 337–41.
9.
go back to reference Zeitler EP, Abraham WT. Novel devices in heart failure: BAT, atrial shunts, and phrenic nerve stimulation. JACC Heart Fail. 2020;8(4):251–64.PubMedCrossRef Zeitler EP, Abraham WT. Novel devices in heart failure: BAT, atrial shunts, and phrenic nerve stimulation. JACC Heart Fail. 2020;8(4):251–64.PubMedCrossRef
10.
go back to reference Paitazoglou C, Bergmann MW, Özdemir R, Pfister R, Bartunek J, Kilic T, Lauten A, Schmeisser A, Zoghi M, Anker SD. One-year results of the first-in-man study investigating the atrial flow regulator for left atrial shunting in symptomatic heart failure patients: the PRELIEVE study. Eur J Heart Fail. 2021;23(5):800–10.PubMedCrossRef Paitazoglou C, Bergmann MW, Özdemir R, Pfister R, Bartunek J, Kilic T, Lauten A, Schmeisser A, Zoghi M, Anker SD. One-year results of the first-in-man study investigating the atrial flow regulator for left atrial shunting in symptomatic heart failure patients: the PRELIEVE study. Eur J Heart Fail. 2021;23(5):800–10.PubMedCrossRef
11.
go back to reference Kaley V, Dahdah N, El-Sisi A, Grohmann J, Rosenthal E, Jones M, Morgan G, Hayes N, Shah A, Karakurt C. Atrial septal defect–associated pulmonary hypertension: outcomes of closure with a fenestrated device. Adv Pulm Hypertens. 2019;18(1):4–9.CrossRef Kaley V, Dahdah N, El-Sisi A, Grohmann J, Rosenthal E, Jones M, Morgan G, Hayes N, Shah A, Karakurt C. Atrial septal defect–associated pulmonary hypertension: outcomes of closure with a fenestrated device. Adv Pulm Hypertens. 2019;18(1):4–9.CrossRef
12.
go back to reference Akseer S, Horlick E, Vishwanath V, Hobbes B, Huszti E, Mak S, Lee DS, Abrahamyan L. Prevalence and outcomes of pulmonary hypertension after percutaneous closure of atrial septal defect: a systematic review and meta-analysis. Eur Respir Rev. 2020;29:158.CrossRef Akseer S, Horlick E, Vishwanath V, Hobbes B, Huszti E, Mak S, Lee DS, Abrahamyan L. Prevalence and outcomes of pulmonary hypertension after percutaneous closure of atrial septal defect: a systematic review and meta-analysis. Eur Respir Rev. 2020;29:158.CrossRef
13.
go back to reference Trevor S, Marino L, Firas Z, Babak N, William G, James H, Sunit-Preet C, Leonardo G, Franois P, Peter E. Percutaneous atriotomy for levoatrial-to-coronary sinus shunting insymptomatic heartfailure: first-in-human experience. JACC Cardiovasc Interv. 2020;13(10):1236–47.CrossRef Trevor S, Marino L, Firas Z, Babak N, William G, James H, Sunit-Preet C, Leonardo G, Franois P, Peter E. Percutaneous atriotomy for levoatrial-to-coronary sinus shunting insymptomatic heartfailure: first-in-human experience. JACC Cardiovasc Interv. 2020;13(10):1236–47.CrossRef
14.
go back to reference Shang X, Liu M, Zhong Y, Wang X, Chen S, Fu X, Sun M, Xie M, Ke Y, Guan Y. Clinical study on the treatment of chronic heart failure with a novel D‐shant atrium shunt device. ESC Heart Fail. 2022. Shang X, Liu M, Zhong Y, Wang X, Chen S, Fu X, Sun M, Xie M, Ke Y, Guan Y. Clinical study on the treatment of chronic heart failure with a novel D‐shant atrium shunt device. ESC Heart Fail. 2022.
15.
go back to reference Griffin JM, Borlaug BA, Komtebedde J, Litwin SE, Shah SJ, Kaye DM, Hoendermis E, Hasenfuß G, Gustafsson F, Wolsk E. Impact of interatrial shunts on invasive hemodynamics and exercise tolerance in patients with heart failure. J Am Heart Assoc. 2020;9(17):e016760.PubMedPubMedCentralCrossRef Griffin JM, Borlaug BA, Komtebedde J, Litwin SE, Shah SJ, Kaye DM, Hoendermis E, Hasenfuß G, Gustafsson F, Wolsk E. Impact of interatrial shunts on invasive hemodynamics and exercise tolerance in patients with heart failure. J Am Heart Assoc. 2020;9(17):e016760.PubMedPubMedCentralCrossRef
16.
go back to reference Nanayakkara S, Kaye DM. Device therapy with interatrial shunt devices for heart failure with preserved ejection fraction. Heart Fail Rev. 2023;28(2):281–6.PubMed Nanayakkara S, Kaye DM. Device therapy with interatrial shunt devices for heart failure with preserved ejection fraction. Heart Fail Rev. 2023;28(2):281–6.PubMed
17.
go back to reference Galiè N, Humbert M, Vachiery J-L, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67–119.PubMedCrossRef Galiè N, Humbert M, Vachiery J-L, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67–119.PubMedCrossRef
18.
go back to reference Vanhie E, VandeKerckhove K, Haas NA, De Wolf D. Atrial flow regulator for drug-resistant pulmonary hypertension in a young child. Catheter Cardiovasc Interv. 2021;97(6):E830–4.PubMedCrossRef Vanhie E, VandeKerckhove K, Haas NA, De Wolf D. Atrial flow regulator for drug-resistant pulmonary hypertension in a young child. Catheter Cardiovasc Interv. 2021;97(6):E830–4.PubMedCrossRef
19.
go back to reference Huang D, Hua W, Fang Q, Yan J, Su Y, Liu B, Xu Y, Peng Y, Investigators PC. Biventricular pacemaker and defibrillator implantation in patients with chronic heart failure in China. ESC Heart Fail. 2021;8(1):546–54.PubMedCrossRef Huang D, Hua W, Fang Q, Yan J, Su Y, Liu B, Xu Y, Peng Y, Investigators PC. Biventricular pacemaker and defibrillator implantation in patients with chronic heart failure in China. ESC Heart Fail. 2021;8(1):546–54.PubMedCrossRef
20.
go back to reference Meng F, Zhang Z, Hou X, Qian Z, Wang Y, Chen Y, Wang Y, Zhou Y, Chen Z, Zhang X. Machine learning for prediction of sudden cardiac death in heart failure patients with low left ventricular ejection fraction: study protocol for a retroprospective multicentre registry in China. BMJ Open. 2019;9(5):e023724.PubMedPubMedCentralCrossRef Meng F, Zhang Z, Hou X, Qian Z, Wang Y, Chen Y, Wang Y, Zhou Y, Chen Z, Zhang X. Machine learning for prediction of sudden cardiac death in heart failure patients with low left ventricular ejection fraction: study protocol for a retroprospective multicentre registry in China. BMJ Open. 2019;9(5):e023724.PubMedPubMedCentralCrossRef
21.
go back to reference Kaye DM, Hasenfuss G, Neuzil P, Post MC, Doughty R, Trochu J-N, Kolodziej A, Westenfeld R, Penicka M, Rosenberg M. One-year outcomes after transcatheter insertion of an interatrial shunt device for the management of heart failure with preserved ejection fraction. Circul Heart Fail. 2016;9(12):e003662.CrossRef Kaye DM, Hasenfuss G, Neuzil P, Post MC, Doughty R, Trochu J-N, Kolodziej A, Westenfeld R, Penicka M, Rosenberg M. One-year outcomes after transcatheter insertion of an interatrial shunt device for the management of heart failure with preserved ejection fraction. Circul Heart Fail. 2016;9(12):e003662.CrossRef
22.
go back to reference Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, Lam CS, Ponikowski P, Voors AA, Jia G. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020;382(20):1883–93.PubMedCrossRef Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, Lam CS, Ponikowski P, Voors AA, Jia G. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020;382(20):1883–93.PubMedCrossRef
23.
go back to reference Upadhya B, Kitzman DW. Heart failure with preserved ejection fraction: new approaches to diagnosis and management. Clin Cardiol. 2020;43(2):145–55.PubMedCrossRef Upadhya B, Kitzman DW. Heart failure with preserved ejection fraction: new approaches to diagnosis and management. Clin Cardiol. 2020;43(2):145–55.PubMedCrossRef
24.
go back to reference Giannitsi S, Bougiakli M, Bechlioulis A, Kotsia A, Michalis LK, Naka KK. 6-minute walking test: a useful tool in the management of heart failure patients. Therap Adv Cardiovasc Dis. 2019;13:1753944719870084. Giannitsi S, Bougiakli M, Bechlioulis A, Kotsia A, Michalis LK, Naka KK. 6-minute walking test: a useful tool in the management of heart failure patients. Therap Adv Cardiovasc Dis. 2019;13:1753944719870084.
25.
go back to reference Capota R, Militaru S, Ionescu AA, Rosca M, Jurcut R. Quality of life status determinants in hypertrophic cardiomyopathy as evaluated by the Kansas City Cardiomyopathy Questionnaire. Health Qual Life Outcomes. 2020;18(1):351.PubMedPubMedCentralCrossRef Capota R, Militaru S, Ionescu AA, Rosca M, Jurcut R. Quality of life status determinants in hypertrophic cardiomyopathy as evaluated by the Kansas City Cardiomyopathy Questionnaire. Health Qual Life Outcomes. 2020;18(1):351.PubMedPubMedCentralCrossRef
26.
go back to reference Zoghbi WA, Levine RA, Flachskampf F, Grayburn P, Gillam L, Leipsic J, Thomas JD, Kwong RY, Vandervoort P, Chandrashekhar Y. Atrial functional mitral regurgitation: a JACC: cardiovascular imaging expert panel viewpoint. JACC Cardiovasc Imaging. 2022;15(11):1870–82.PubMedCrossRef Zoghbi WA, Levine RA, Flachskampf F, Grayburn P, Gillam L, Leipsic J, Thomas JD, Kwong RY, Vandervoort P, Chandrashekhar Y. Atrial functional mitral regurgitation: a JACC: cardiovascular imaging expert panel viewpoint. JACC Cardiovasc Imaging. 2022;15(11):1870–82.PubMedCrossRef
27.
go back to reference Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol. 2000;35(5):1245–55.PubMedCrossRef Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol. 2000;35(5):1245–55.PubMedCrossRef
28.
go back to reference Creber RM, Polomano R, Farrar J, Riegel B. Psychometric properties of the Kansas City cardiomyopathy questionnaire (KCCQ). Eur J Cardiovasc Nurs. 2012;11(2):197–206.PubMedCentralCrossRef Creber RM, Polomano R, Farrar J, Riegel B. Psychometric properties of the Kansas City cardiomyopathy questionnaire (KCCQ). Eur J Cardiovasc Nurs. 2012;11(2):197–206.PubMedCentralCrossRef
29.
go back to reference Feldman T, Foster E, Glower DD, Kar S, Rinaldi MJ, Fail PS, Smalling RW, Siegel R, Rose GA, Engeron E. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med. 2011;364(15):1395–406.PubMedCrossRef Feldman T, Foster E, Glower DD, Kar S, Rinaldi MJ, Fail PS, Smalling RW, Siegel R, Rose GA, Engeron E. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med. 2011;364(15):1395–406.PubMedCrossRef
30.
go back to reference Nakwan N, Jain S, Kumar K, Hosono S, Hammoud M, Elsayed YY, Ariff S, Hasan B, Khowaja W, Poon WB. An Asian multicenter retrospective study on persistent pulmonary hypertension of the newborn: incidence, etiology, diagnosis, treatment and outcome. J Matern Fetal Neonatal Med. 2020;33(12):2032–7.PubMedCrossRef Nakwan N, Jain S, Kumar K, Hosono S, Hammoud M, Elsayed YY, Ariff S, Hasan B, Khowaja W, Poon WB. An Asian multicenter retrospective study on persistent pulmonary hypertension of the newborn: incidence, etiology, diagnosis, treatment and outcome. J Matern Fetal Neonatal Med. 2020;33(12):2032–7.PubMedCrossRef
31.
go back to reference Ranchoux B, Nadeau V, Bourgeois A, Provencher S, Tremblay É, Omura J, Coté N, et al. Metabolic syndrome exacerbates pulmonary hypertension due to left heart disease. Circ Res. 2019;125(4):449–66.PubMedCrossRef Ranchoux B, Nadeau V, Bourgeois A, Provencher S, Tremblay É, Omura J, Coté N, et al. Metabolic syndrome exacerbates pulmonary hypertension due to left heart disease. Circ Res. 2019;125(4):449–66.PubMedCrossRef
32.
go back to reference Kaemmerer H, Apitz C, Brockmeier K, Eicken A, Gorenflo M, Hager A, de Haan F, Huntgeburth M, Kozlik-Feldmann RG, Miera O. Pulmonary hypertension in adults with congenital heart disease: updated recommendations from the Cologne Consensus Conference 2018. Int J Cardiol. 2018;272:79–88.CrossRef Kaemmerer H, Apitz C, Brockmeier K, Eicken A, Gorenflo M, Hager A, de Haan F, Huntgeburth M, Kozlik-Feldmann RG, Miera O. Pulmonary hypertension in adults with congenital heart disease: updated recommendations from the Cologne Consensus Conference 2018. Int J Cardiol. 2018;272:79–88.CrossRef
33.
go back to reference Rich S, Lam W. Atrial septostomy as palliative therapy for refractory primary pulmonary hypertension. Am J Cardiol. 1983;51(9):1560–1.PubMedCrossRef Rich S, Lam W. Atrial septostomy as palliative therapy for refractory primary pulmonary hypertension. Am J Cardiol. 1983;51(9):1560–1.PubMedCrossRef
34.
go back to reference Rich S, Dodin E, McLaughlin VV. Usefulness of atrial septostomy as a treatment for primary pulmonary hypertension and guidelines for its application. Am J Cardiol. 1997;80(3):369–71.PubMedCrossRef Rich S, Dodin E, McLaughlin VV. Usefulness of atrial septostomy as a treatment for primary pulmonary hypertension and guidelines for its application. Am J Cardiol. 1997;80(3):369–71.PubMedCrossRef
35.
go back to reference Lammers AE, Derrick G, Haworth SG, Bonhoeffer P, Yates R. Efficacy and long-term patency of fenestrated amplatzer devices in children. Catheter Cardiovasc Interv. 2007;70(4):578–84.PubMedCrossRef Lammers AE, Derrick G, Haworth SG, Bonhoeffer P, Yates R. Efficacy and long-term patency of fenestrated amplatzer devices in children. Catheter Cardiovasc Interv. 2007;70(4):578–84.PubMedCrossRef
36.
go back to reference Kerstein D, Levy PS, Hsu DT, Hordof AJ, Gersony WM, Barst RJ. Blade balloon atrial septostomy in patients with severe primary pulmonary hypertension. Circulation. 1995;91(7):2028–35.PubMedCrossRef Kerstein D, Levy PS, Hsu DT, Hordof AJ, Gersony WM, Barst RJ. Blade balloon atrial septostomy in patients with severe primary pulmonary hypertension. Circulation. 1995;91(7):2028–35.PubMedCrossRef
37.
go back to reference Baglini R. Atrial septostomy in patients with end-stage pulmonary hypertension. No more needles but wires, energy and close anatomical definition. J Interv Cardiol. 2013;26(1):62–8.PubMedCrossRef Baglini R. Atrial septostomy in patients with end-stage pulmonary hypertension. No more needles but wires, energy and close anatomical definition. J Interv Cardiol. 2013;26(1):62–8.PubMedCrossRef
38.
go back to reference Obokata M, Reddy YN, Shah SJ, Kaye DM, Gustafsson F, Hasenfuβ G, Hoendermis E, Litwin SE, Komtebedde J, Lam C. Effects of interatrial shunt on pulmonary vascular function in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2019;74(21):2539–50.PubMedCrossRef Obokata M, Reddy YN, Shah SJ, Kaye DM, Gustafsson F, Hasenfuβ G, Hoendermis E, Litwin SE, Komtebedde J, Lam C. Effects of interatrial shunt on pulmonary vascular function in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2019;74(21):2539–50.PubMedCrossRef
39.
go back to reference Amat-Santos IJ, Bergeron S, Bernier M, Allende R, Ribeiro HB, Urena M, Pibarot P, Verheye S, Keren G, Yaacoby M. Left atrial decompression through unidirectional left-to-right interatrial shunt for the treatment of left heart failure: first-in-man experience with the V-Wave device. EuroInterv J EuroPCR Collab Work Group Interv Cardiol Eur Soc Cardiol. 2015;10(9):11278. Amat-Santos IJ, Bergeron S, Bernier M, Allende R, Ribeiro HB, Urena M, Pibarot P, Verheye S, Keren G, Yaacoby M. Left atrial decompression through unidirectional left-to-right interatrial shunt for the treatment of left heart failure: first-in-man experience with the V-Wave device. EuroInterv J EuroPCR Collab Work Group Interv Cardiol Eur Soc Cardiol. 2015;10(9):11278.
40.
go back to reference Patel MB, Samuel BP, Girgis RE, Parlmer MA, Vettukattil JJ. 13. Implantable atrial flow regulator for severe irreversible pulmonary arterial hypertension. In: Pediatric and adult interventional cardiac symposium: 2015; 2015. Patel MB, Samuel BP, Girgis RE, Parlmer MA, Vettukattil JJ. 13. Implantable atrial flow regulator for severe irreversible pulmonary arterial hypertension. In: Pediatric and adult interventional cardiac symposium: 2015; 2015.
41.
go back to reference Zheng W, Wang Z, Jiang X, Zhao Q, Shen J. Targeted drugs for treatment of pulmonary arterial hypertension: past, present, and future perspectives. J Med Chem. 2020;63(24):15153–86.CrossRef Zheng W, Wang Z, Jiang X, Zhao Q, Shen J. Targeted drugs for treatment of pulmonary arterial hypertension: past, present, and future perspectives. J Med Chem. 2020;63(24):15153–86.CrossRef
42.
go back to reference Rozkovec A, Montanes P, Oakley C. Factors that influence the outcome of primary pulmonary hypertension. Heart. 1986;55(5):449–58.CrossRef Rozkovec A, Montanes P, Oakley C. Factors that influence the outcome of primary pulmonary hypertension. Heart. 1986;55(5):449–58.CrossRef
43.
go back to reference Cuthbert JJ, Pellicori P, Clark AL. Interatrial shunt devices for heart failure with normal ejection fraction: a technology update. Medical Devices. 2017;10:123.PubMedPubMedCentralCrossRef Cuthbert JJ, Pellicori P, Clark AL. Interatrial shunt devices for heart failure with normal ejection fraction: a technology update. Medical Devices. 2017;10:123.PubMedPubMedCentralCrossRef
44.
go back to reference Micheletti A, Hislop A, Lammers A, Bonhoeffer P, Derrick G, Rees P, Haworth SG. Role of atrial septostomy in the treatment of children with pulmonary arterial hypertension. Heart. 2006;92(7):969–72.PubMedCrossRef Micheletti A, Hislop A, Lammers A, Bonhoeffer P, Derrick G, Rees P, Haworth SG. Role of atrial septostomy in the treatment of children with pulmonary arterial hypertension. Heart. 2006;92(7):969–72.PubMedCrossRef
45.
go back to reference Rajeshkumar R, Pavithran S, Sivakumar K, Vettukattil JJ. Atrial septostomy with a predefined diameter using a novel occlutech atrial flow regulator improves symptoms and cardiac index in patients with severe pulmonary arterial hypertension. Catheter Cardiovasc Interv. 2017;90(7):1145–53.PubMedCrossRef Rajeshkumar R, Pavithran S, Sivakumar K, Vettukattil JJ. Atrial septostomy with a predefined diameter using a novel occlutech atrial flow regulator improves symptoms and cardiac index in patients with severe pulmonary arterial hypertension. Catheter Cardiovasc Interv. 2017;90(7):1145–53.PubMedCrossRef
46.
go back to reference Haass M, Kitzman DW, Anand IS, Miller A, Zile MR, Massie BM, Carson PE. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circul Heart Fail. 2011;4(3):324–31.CrossRef Haass M, Kitzman DW, Anand IS, Miller A, Zile MR, Massie BM, Carson PE. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circul Heart Fail. 2011;4(3):324–31.CrossRef
47.
go back to reference Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Woo MA, Tillisch JH. The relationship between obesity and mortality in patients with heart failure. J Am Coll Cardiol. 2001;38(3):789–95.PubMedCrossRef Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Woo MA, Tillisch JH. The relationship between obesity and mortality in patients with heart failure. J Am Coll Cardiol. 2001;38(3):789–95.PubMedCrossRef
48.
go back to reference Subki AH, Almalki M, Butt NS, Alsallum MS, Alghalayini KW. Echocardiographic and clinical correlates of ejection fraction among 2000 patients with heart failure in Western Saudi Arabia. Int J Gener Med. 2020;13:281–8.CrossRef Subki AH, Almalki M, Butt NS, Alsallum MS, Alghalayini KW. Echocardiographic and clinical correlates of ejection fraction among 2000 patients with heart failure in Western Saudi Arabia. Int J Gener Med. 2020;13:281–8.CrossRef
Metadata
Title
Short-term study of atrial shunt and improvement of functional mitral regurgitation
Authors
Xiaoke Shang
Mei Liu
Yucheng Zhong
Xueli Wang
Song Chen
Xiaojuan Fu
Ming Sun
Geng Li
Mingxing Xie
Guangyuan Song
Da Zhu
Changdong Zhang
Nianguo Dong
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Journal of Cardiothoracic Surgery / Issue 1/2023
Electronic ISSN: 1749-8090
DOI
https://doi.org/10.1186/s13019-023-02398-9

Other articles of this Issue 1/2023

Journal of Cardiothoracic Surgery 1/2023 Go to the issue